TELA Bio, Inc.
TELA · Price history
Price at last available close
$0.92
−$0.32 (-25.81%) 1M
2026-10-29
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About TELA Bio, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States.
How they make money
TELA Bio is a commercial-stage medical technology company that generates revenue primarily through the sale of its proprietary soft-tissue reconstruction products to hospitals and surgery centers. The company utilizes a direct sales force and distribution network to market its products, which are designed to optimize clinical outcomes in hernia repair and plastic and reconstructive surgery.
Products & services
The company offers the OviTex Reinforced Tissue Matrix and OviTex PRS product lines, which are FDA-cleared devices that incorporate polymer fibers interwoven through layers of biologic material derived from ovine rumen to reinforce soft tissue.
Brands & revenue mix
Reinforced Tissue Matrix for hernia repair and abdominal wall reconstruction.
Separate brand revenue is not available in this research.Source
Reinforced Tissue Matrix for plastic and reconstructive surgery.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer concentration
The company does not disclose specific customer concentration figures in its 2025 annual report.
Suppliers, materials & equipment
- Aroa Biosurgery Ltd. — Exclusive contract manufacturer for the company's OviTex and OviTex PRS product lines.Source
Business relationships & partnerships
- Aroa Biosurgery Ltd. — Aroa serves as the exclusive contract manufacturer for TELA Bio's OviTex and OviTex PRS products and holds the FDA 510(k) clearances for these products.Source
Strengths
- Proprietary embroidered construction of biologic matrix and polymer fibersSource
Risks
- Reliance on a single contract manufacturer (Aroa) for all product supplySource
Sources
Financial risk observations and what to check
These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-06-30.
Diluted weighted-average shares increased 26.6% year over year.
Compare per-share results with total earnings and inspect the equity footnote. A change in weighted-average shares does not by itself establish the cause, the number of shares issued today, or the economic effect of a split.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
16
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
18
Poor
Financial Strength
13
Business Quality / Moat
10
Management
33
Growth Quality
20
Risk / Durability
15
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
35
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
43/100
Building Historical Record
Model Score 43/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Insider activity signal is favorable
- •Recent buyback activity is present
- •Debt service risk
- •M&A headline · Sep 21, 2026
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
Company-specific research
Questions worth answering for TELA
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving TELA's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •How long can TELA fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Does TELA's balance between cash and debt leave enough flexibility if business conditions weaken?
- •What specifically needs to improve for TELA to reach sustainable profitability?
- •What future growth or profitability would be needed to justify TELA's current valuation?
Essential Investment Snapshot
Wall Street Score
16
Opportunity Score
35
Market Cap
$41.5M
P/E Ratio
-1.5
EPS
$-0.77
52-Week High
$1.52
52-Week Low
$0.50
Beta
1.36
Analyst Target
$2.00
Shares Outstanding
46.9M
Total Revenue
$79.9M
Total Debt
$56.6M
Dividend
No current dividend
Liquidation Value / Share
$-0.34
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Elevated movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for TELA
Detected from reported data — verify before acting.Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Debt service risk
Interest coverage is low (~-6.4x). Earnings may be strained to cover interest expense.
M&A headline · Sep 21, 2026
Insider Buying: TELA Bio (NASDAQ:TELA) Director Acquires $30,500.00 in Stock — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
Defense WorldCommunity Sentiment
0 active · 0 total callsNo personal call yet on TELA.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary embroidered construction of biologic matrix and polymer fibers.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Devices industry.
- −Reliance on a single contract manufacturer (Aroa) for all product supply.
- −Diluted weighted-average shares increased 26.6% year over year.
- −Negative free cash flow may increase the need for outside financing and dilution.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
3 historical score records availablePrevious Score
16
Oct 1, 2026
Change
+0.1
points
Current Score
16
Oct 22, 2026
Category Changes
TELA increased 0.1 points because overall fundamentals improved.
Projected Score
Projected Score
11
Projected Change
-4.8 points
Preliminary comparable-period financial changes suggest decline of approximately 4.8 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$0.92
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $79.9M | $80.3M | $69.3M | $58.5M | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $25.7M | $25.9M | $22.8M | $18.3M | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $54.2M | $54.3M | $46.5M | $40.1M | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $9.5M | $9.2M | $8.8M | $9.6M | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $78.7M | $78.9M | $79.4M | $74.6M | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $88.2M | $88.1M | $80.6M | $84.2M | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$32.9M | -$32.3M | -$31.7M | -$40.6M | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$34.0M | -$33.8M | -$34.1M | -$44.1M | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $2.9M | $5.2M | $5.3M | $5.2M | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$40.9M | -$38.6M | -$38.0M | -$46.7M | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $265K | $230K | -$144K | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$41.2M | -$38.8M | -$37.8M | -$46.7M | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-0.77 | $-0.83 | $-1.33 | $-2.04 | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 57.41M | 46.95M | 28.53M | 22.87M | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 57.41M | 46.95M | 28.53M | 22.87M | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$19.3M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.20
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+35.1%
Cash Change
-13.0%
Margin Change
-9.2 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Weakened
- Margins contracted
- Cash position declined
- Debt increased
Potential Score Impact
Pressure indicators included revenue growth, EPS growth, cash levels, debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue declined 4.5%. EPS declined 9.1%. Cash declined 13.0%. Total debt increased 35.1%. Net income margin declined by 9.2 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - DevicesNews
TELA Bio, Inc. (TELA) Shareholder/Analyst Call Transcript
TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement
Insider Buying: TELA Bio (NASDAQ:TELA) Director Acquires $30,500.00 in Stock
TELA Bio (NASDAQ:TELA) versus Baxter International (NYSE:BAX) Head to Head Analysis
Rumor Mill · TELA
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial